A copper compound sold for skin has only two trials in people, review finds

Walk down the skin care aisle and the words copper peptide turn up on serums, creams and eye gels. Most of these products use one molecule, a tiny piece of protein that holds a bit of copper. Its short name is GHK-Cu, and it has been studied for more than thirty years [1][3].

A new review counted that research and found it is mostly not in people. Of 20 studies that fit the rules, 18 were done in cells or animals. Only 2 were trials in people where chance decided who got the compound and who got a comparison [1].

That is the main caveat, and it is worth saying plainly. Two small trials in people are not enough to say what the compound does for human skin, and the review says so itself [1].

The review was led by Jonathan Mokhtar of the Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai. It was published in 2026 in Aesthetic Surgery Journal. A systematic review like this gathers all the research on one question using fixed rules, so no study is picked just because it agrees [1].

What did the lab studies find?

The team searched three big lists of science papers, PubMed, Embase and Cochrane CENTRAL, from their start up to March 2026. In cells and animals, the results pointed the same way. The compound raised the amount of type I collagen, a protein that gives skin its strength. It raised other building materials of skin, helped new blood vessels form and calmed two signals of swelling. Tiny needles and tiny fat bubbles moved more of it through the skin than simply putting it on [1].

In people, the review reports higher patient satisfaction after laser treatment, and smaller wrinkles than in comparison groups. But a short summary cannot show how big those trials were or how well they were run. The authors weighed the whole body of work like this:

Nevertheless, the findings reported across studies were constrained by methodological variability and a limited number of well-designed clinical trials.

Mokhtar and colleagues, Aesthetic Surgery Journal, 2026 [1]

In plain words, the studies were done in too many different ways to compare well, and there are too few good trials in people [1].

What does a trial in people look like up close?

A 2006 trial in Archives of Facial Plastic Surgery shows how thin such evidence can be. Patients had skin around the mouth treated with a carbon dioxide laser, which removes the top layers of skin. Chance then put them into two groups with the same skin care routine, except only one routine held the copper compound. Thirteen patients finished [2].

A computer program and graders who did not know who was in which group checked the redness. They found no difference. Every patient's wrinkles improved over 12 weeks, but again the groups did not differ. The authors wrote:

Objective evaluation found no significant improvement in wrinkles or overall skin quality.

Miller and colleagues, Archives of Facial Plastic Surgery, 2006 [2]

In plain words, measured from the outside, the compound made no difference. Only one result split the groups. On a form patients filled out themselves, the copper group rated their skin quality higher. Self reports are the weakest kind of evidence about how skin looks, yet this is the result repeated most often [2].

An even older trial, from 1992, tested a 0.4 percent copper cream on slow healing leg sores in 86 patients. A germ fighting silver cream shrank the sores more. Between the copper cream and a plain cream with nothing active in it, there was no difference [3].

Newer work stays mostly in the lab. A 2026 study in Biogerontology, a journal about aging, gave the compound to tiny roundworms about one millimetre long. The worms lived longer and coped better with heat and wear and tear on their cells. A worm is a long way from a human face, and the study does not claim otherwise [4].

The United States Food and Drug Administration has also put the injected form on a list of ingredients that may carry serious safety risks. The list covers medicines that pharmacies mix for patients. It said the shots might set off the immune system, and that there is little data in people. That is not a finding of harm, and it does not cover creams [5].

So the lab evidence points the same way again and again, but the trials in people are few and small. This review does not show that the compound smooths wrinkles or heals skin in people. It does show where the evidence stands, and its authors call for larger trials with the same preparation and amounts [1].